• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

PCV13: Effective Against First-Episode CAP in Older Adults

Slideshow

The 13-valent pneumococcal conjugate vaccine reduced nearly by half vaccine-type community acquired pneumonia in adults aged 65 years and older.

Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
Pfizer Reports Topline Data for Abrysvo Against RSV in Younger High-Risk Adults ©cbies/stock.adobe.com

Pfizer Reports Topline Data for Abrysvo Against RSV in Younger High-Risk Adults

Grace Halsey
August 12th 2024
Article

RSVPreF induced strong neutralizing responses in immunocompromised adults aged 18 years and older in substudy B of the ongoing phase 3 MONET clinical trial.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

ME/CFS Rates No Different After COVID-19 Infection than After Other Acute Infection-Like Illnesses / image credit body in pain: ©Lila Patel via AI/stock.adobe.com

ME/CFS Rates No Different After COVID-19 Infection than After Other Acute Infection-Like Illnesses

Grace Halsey
July 24th 2024
Article

The rate of ME/CFS was similar (3% to 4%) at 3 through 12 months for study participants who tested positive and negative for COVID-19.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

FDA Gives Green Light to Ensifentrine for Maintenance Treatment of COPD in Adults / image credit ©Waldenmarus/stock.adobe.com

FDA Gives Green Light to Ensifentrine for Maintenance Treatment of COPD in Adults

Brooke McCormick
June 27th 2024
Article

The dual PDE3/PDE4 inhibitor is the first inhaled product with a novel mechanism of action approved for COPD in 2 decades and is delivered via standard jet nebulizer.

Investigational Influenza-COVID-19 Combination Vaccine Elicits Immune Response in Older Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Investigational Influenza-COVID-19 Combination Vaccine Elicits Immune Response in Older Adults: Daily Dose

Sydney Jennings
June 20th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.